Form 4: Genmab Boosts Merus Stake Post-Tender Offer

Genmab A/S, through its subsidiary, acquired additional common shares of Merus N.V. at $97 per share following a tender offer, increasing its beneficial ownership to over 71.7 million shares.

Summary

• Genmab A/S, through its wholly-owned subsidiary Genmab Holding II B.V. (Purchaser), increased its beneficial ownership in Merus N.V.
• The acquisitions occurred on December 16, 2025, and December 17, 2025, during a subsequent offering period.
• On December 16, 2025, Purchaser acquired 120,752 common shares of Merus N.V. at a price of $97 per share.
• On December 17, 2025, Purchaser acquired an additional 150,795 common shares of Merus N.V. at $97 per share.
• These transactions followed an initial tender offer that expired on December 12, 2025, where Purchaser accepted 71,463,077 common shares, representing approximately 94.2% of Merus's outstanding shares, also at $97 per share.
• Following these transactions, Genmab A/S beneficially owns 71,734,624 common shares of Merus N.V.

Sentiment

Score: 8

Explanation: The filing details the successful progression of a tender offer, with Genmab A/S significantly increasing its beneficial ownership in Merus N.V. at a consistent price. This indicates a positive strategic move for Genmab A/S, solidifying its control and integration plans for Merus N.V., which is generally viewed favorably for the acquiring entity's strategic objectives.

Positives

• Genmab A/S has significantly increased its stake in Merus N.V., demonstrating strong commitment and confidence in the company's future.
• The successful tender offer and subsequent acquisitions indicate a high level of shareholder acceptance for the $97 per share offer price.
• Increased ownership provides Genmab A/S with greater control and influence over Merus N.V.'s strategic direction.

Negatives

• The tender offer price of $97 per share might be considered low by some Merus N.V. shareholders who did not tender their shares.
• Merus N.V. is now largely controlled by Genmab A/S, potentially reducing its independent operational flexibility.

Risks

• Integration risks associated with Genmab A/S's increased control and potential future full acquisition of Merus N.V.
• Potential for remaining minority shareholders in Merus N.V. to challenge the terms or process of the acquisition.

Future Outlook

The filing indicates Genmab A/S's near-complete acquisition of Merus N.V., suggesting a future where Merus N.V. will likely operate as a subsidiary or be fully integrated into Genmab A/S, potentially leading to delisting or further consolidation.

Management Comments

• Genmab A/S, as the parent entity of Purchaser, beneficially owns the Common Shares held directly by Purchaser.

Industry Context

This transaction reflects a broader trend of consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire innovative smaller firms to expand their pipelines and market reach. Genmab A/S, a leader in antibody therapeutics, is strengthening its position by integrating Merus N.V.'s proprietary Biclonics® technology and clinical programs, which aligns with strategic growth through M&A in the highly competitive oncology and immunology spaces.

Comparison to Industry Standards

• The acquisition price of $97.00 per share for Merus N.V. should be evaluated against recent M&A transactions in the oncology and immunology biotechnology space, considering Merus's clinical pipeline, intellectual property, and market capitalization prior to the offer.
• For example, comparable acquisitions like Gilead Sciences' acquisition of Immunomedics for $21 billion (approximately $88 per share) or Bristol Myers Squibb's acquisition of Celgene for $74 billion, while larger in scale, provide context for valuation multiples based on pipeline stage, therapeutic area, and revenue potential.
• The high acceptance rate of 94.2% in the initial tender offer suggests the offer price was compelling to a significant majority of Merus shareholders, indicating it was likely at a premium to the pre-announcement trading price, consistent with industry acquisition premiums.

Stakeholder Impact

• Shareholders (Merus N.V.): Those who tendered shares received $97.00 per share. Remaining minority shareholders face potential illiquidity or a future squeeze-out.
• Shareholders (Genmab A/S): The acquisition strengthens Genmab's pipeline and market position, potentially leading to long-term value creation.
• Employees (Merus N.V.): Integration into Genmab A/S may lead to organizational restructuring, though the filing does not specify.
• Customers/Partners (Merus N.V.): Potential for enhanced resources and broader market access through Genmab A/S's network.

Next Steps

• Potential for Genmab A/S to initiate a squeeze-out or delisting process for the remaining Merus N.V. shares, given the high ownership percentage (over 94%).
• Integration of Merus N.V.'s operations and pipeline into Genmab A/S.

Key Dates

Recommendation

For Merus N.V. shareholders, with Genmab A/S now owning over 94% of outstanding shares, the company is effectively controlled by Genmab. Remaining shareholders are likely to face a mandatory squeeze-out or delisting, making 'hold' the appropriate stance until further details on the squeeze-out process or delisting are announced. For Genmab A/S, this filing confirms the successful execution of a strategic acquisition, which is generally positive for long-term growth, but the immediate stock reaction would depend on the market's assessment of the acquisition's valuation and synergy potential, warranting a 'hold' for existing investors to observe integration progress.

Keywords

Genmab A/S, Merus N.V., MRUS, Tender Offer, Share Acquisition, Beneficial Ownership, SEC Form 4, Biotechnology, Pharmaceuticals, M&A